Worldwide Biotech/Biopharma Alliance (May 9, 2013～May 6, 2013)
On May 9, 2013, GlaxoSmithKline and Merck are slashing the prices of their HPV vaccinations in a deal with the GAVI Alliance, which delivers immunizations to the developing world. It's the first big push to protect girls in poor countries from the human papillomavirus, which can cause cervical cancer.
On May 8, 2013, Zhejiang Huahai Pharma has joined with Oncobiologics to form a partnership that will develop, manufacture and promote biosimilars. Huahai will have exclusive rights to make and market four Oncobiologics-developed biosimilars in China. The two companies will also sign a co-development and commercialization agreement to bring the four products -- generic versions of Humira, Rituxan, Avastin and Herceptin -- to 30 developed countries.
On May 7, 2013, DBV Technologies, creator of Viaskin, a new standard in the treatment of allergies, announced a partnership with the Jaffe Food Allergy Institute at the Icahn School of Medicine for research related to the mechanism by which epicutaneous immunotherapy using Viaskin leads to immune tolerance to food antigens.
On May 6, 2013, Proteros biostructures GmbH announced the successful completion of an integrated lead discovery collaboration with Eisai Co., Ltd. Based on Proteros’ structure guided discovery platform, various series of Lead Compounds were developed within a period of 10 months. The developed compound series showed single digit nanomolar Kd values, as well as optimized binding kinetics and kinetic selectivity. Hits were identified out of the Proteros fragment library and the optimization process was driven by high quality protein crystallography as well as kinetic and thermodynamic profiling and the seamless interactions between Eisai and Proteros medicinal and computational chemists.
On May 6, 2013, Concert Pharmaceuticals CEO Roger Tung has reeled in his third collaboration deal in a little more than a year, inking a $300 million pact with Celgene to tweak cancer and anti-inflammatory drugs with its deuterium-stabilizing technology.
Article Link: Worldwide Biotech/Biopharma Alliance (May 9, 2013 ～ May 6, 2013)
Tags: Alliance/Cooperation, Cancer, Diagnostic Antigen, Biosimilar, Protein Crystallography